Condition: Melanoma Metastatic · Melanoma, Skin · Melanoma Stage III or IV · Sponsor: Pamgene International B.V.
The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma). For this purpose it is evaluated how well the IOpener-melanoma test can predict the result of cancer treatment in the treatment groups (standard of care anti-PD1 mono-therapy and standard of care anti-PD1 + anti-CTLA-4 therapy). Participants will be asked to provide blood sample for analysis using IOpener®-melanoma test. Patients will receive regular medical care, the test results will not be used to make any treatment decisions. The patients will visit the clinic for treatment administration and clinical evaluation as part of their regular medical care.
This description comes directly from the study's public registry record.
Project Leader Clinical Trials · + 31 (0) 73 615 80 71 · dvdheuvel@pamgene.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Tübingen | Tübingen, Baden-Wurttemberg, Germany | Recruiting |
| Heidelberg University Hospital | Heidelberg, Germany | Recruiting |
| LMU Klinikum | München, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06784778